Recipient	Award amount
Partnership for Trauma Recovery, Berkeley, California	30,000
Program for Torture Victims LA County, Los Angeles, California	20,000
The Center for Victims of Torture, Atlanta, Georgia	$3,000
The Center for Victims of Torture, St. Paul, Minnesota	70,000

These programs will provide direct services to the 222 Nicaraguan Humanitarian Parolees (NHP) who were released from prison in Nicaragua and brought to the United States by the U.S. Department of State in February 2023.

On February 16, 2023, ORR issued Dear Colleague Letter 23–16, which stated that while the NHP's current immigration status does not provide eligibility for refugee program assistance, they may apply for assistance from ORR-funded Survivors of Torture (SOT) grant recipients. ORR has been working closely with the U.S. Department of State to connect these individuals to SOT grant recipients and other local service providers. Due to the nature and length of the NHP's detention in Nicaragua, their sudden release from prison and entry into the United States, and their temporary immigration status, these individuals need immediate assistance. The SOT grant recipients identified above are willing to provide medical, mental health, case management, and legal services to these individuals. However, the timing of these arrivals and the concentration in certain states has overwhelmed the capacity of SOT grant recipients in these locations. The supplemental awards will enhance the grant recipients' capacity to provide essential care and support for NHP so that they can begin the healing process.

Statutory Authority: Section 5(a) of the ''Torture Victims Relief Act of 1998,'' Public Law 105–320 (22 U.S.C. 2152 note) Assistance for Treatment of Torture Victims.

Karen D. Shields,

Senior Grants Policy Specialist, Office of Grants Policy, Office of Administration.

[FR Doc. 2023–15650 Filed 7–24–23; 8:45 am]

BILLING CODE 4184–46–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2023–N–0155]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quantitative Research on Front of Package Labeling on Packaged Foods; Reopening of the Comment Period

AGENCY: Food and Drug Administration, Department of Health and Human Services (HHS).

ACTION: Notice; reopening of the comment period.

SUMMARY: The Food and Drug Administration (FDA or we) is reopening the comment period for the notice entitled ''Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Quantitative Research on Front of Package Labeling on Packaged Foods,'' published in the **Federal Register** of June 15, 2023, to allow interested parties additional time to submit comments. We are taking this action due to technical difficulties experienced on the final two days of the comment period that may have prevented some interested parties from submitting comments.

DATES: FDA is reopening the comment period on the notice published on June 15, 2023 (88 FR 39257). Submit written comments (including recommendations) on the collection of information by 11:59 p.m. on Wednesday, July 26, 2023.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to *https://www.reginfo.gov/public/do/PRA/icrPublicCommentRequest?ref_nbr=202306-0910-004*. You may also find this particular information collection at *https://www.reginfo.gov/public/do/PRAMain* by following these instructions: Under the header ''Currently under Review Select Agency'' use the drop down menu to select ''Department of Health and Human Services'' or by using the search function. The title of this information collection is ''Quantitative Research on Front of Package Labeling on Packaged Foods.'' Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North, 10A–12M, 11601 Landsdown St., North Bethesda, MD 20852, 301–796–3794, *PRAStaff@fda.hhs.gov*.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of June 15, 2023 (88 FR 39257), FDA announced that a proposed collection of information had been submitted to the Office of Management and Budget for review and clearance under the Paperwork Reduction Act of 1995. Interested parties were originally given until July 17, 2023, to submit comments (including recommendations) on the information collection.

However, on July 16 and 17, 2023, technical difficulties may have prevented some stakeholders from submitting electronic comments. Therefore, we are reopening the comment period to allow interested parties additional time to submit comments. The reopened comment period provides an opportunity for stakeholders who may have been impacted by the technical difficulties.

Dated: July 19, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

[FR Doc. 2023–15639 Filed 7–24–23; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket Nos. FDA–2022–D–0055 and FDA–2020–N–1790]

M7(R2) Assessment and Control of Deoxyribonucleic Acid Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk, M7(R2) Addendum, and M7(R2) Questions and Answers; International Council for Harmonisation; Guidances for Industry; Availability

AGENCY: Food and Drug Administration, HHS.